Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Press Release

Identifying the mechanism of action could be key to gaining regulatory approval for microbiome therapeutics, says GlobalData

Identifying the mechanism of action is anticipated to be a key challenge in developing and launching microbiome therapeutics, according to GlobalData, a leading data and analytics company. The company’s latest report ‘The State of the Microbiome’ – based on the results of a 10 minute survey of 158 GlobalData Pharma clients and prospects that was […]
Read more

Profit soars as sales growth slows for Amazon, says GlobalData

Following yesterday’s (31st January 2019) Q4 2018 results from Amazon, Neil Saunders, Managing Director at GlobalData Retail offer his view: “Overall, Amazon has ended its fiscal year on a positive note. However, there is now a clear divergence in performance between the top and bottom lines – with the latter accelerating and the former decelerating. […]
Read more

Real-world data successfully used to predict the risk of chronic kidney disease in patients with diabetes, says GlobalData

Chronic kidney disease (CKD) has a low diagnosis rate which will continue through 2026 unless there are more effective ways to diagnose CKD, according to GlobalData, a leading data and analytics company. A research collaboration between Roche, IBM, and other partners successfully used real-world data (RWD) to calculate the risk of CKD in patients with […]
Read more

First ‘Digital Pill’ in oncology aims to improve outcomes and adherence for patients, says GlobalData

Following the recent announcement by Proteus Digital Health that sensor-embedded oral chemotherapy tablets could help to improve medication adherence, Amrita Gujral, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the impact this new dosing form could have in the oncology industry: “With the high cost, complex regimens and toxic […]
Read more

New blood test could predict Alzheimer’s disease and other neurodegenerative diseases earlier, says GlobalData

Following the news (21st January 2019) that, according to a study published in Nature Medicine, a new blood test could detect Alzheimer’s disease (AD) and other neurodegenerative diseases more than 10 years earlier, Alessio Brunello, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Finding a biomarker in AD that translates […]
Read more

Wearable technology to play an important role in early diagnosis of psychiatric illness in children, says GlobalData

Following the news that wearable technology could help diagnose disorders in children earlier, Bishal Bhandari, Epidemiologist at GlobalData, a leading data and analytics company, offers his view on the impact of this on the wearable market: “Wearable technology is already well established in monitoring general health and used by athletes or those wanting to live […]
Read more

Whitbread set to ride out any post-Brexit storm following Q3 results, says GlobalData

Following today’s (17 January 2019) announcement of Whitbread’s Q3 trading results, Nick Wyatt, Head of Tourism at GlobalData, offers his view on the company’s future: “Superficially, Whitbread’s year-to-date numbers look very positive. Year-to-date, year-on-year accommodation revenue growth is an impressive 4.1%, but a deeper look suggests the situation is not quite as rosy as it […]
Read more

Bristol-Myers Squibb continues to strengthen its immuno-oncology presence with approval for PD-1 inhibitor Opdivo in untreated renal cell carcinoma, says GlobalData

Following the news that the European Commission have approved Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) for previously untreated intermediate- or poor-risk advanced renal cell carcinoma, Chloé Thépaut, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the company’s position: ‘‘The approval of BMS’ in-house IO combination, […]
Read more
1 … 37 38 39 40 41 … 61